This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Bullous Pemphigoid, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling pric...

Cancer, a life-threatening disease, also has genetic origins, and is considered among the leading causes of death across the globe. In fact, the World Health Organization (WHO) has reported that close to 10 million cancer related deaths annually, across the world. As a result, this disease area is characterized by a significant unmet need for curative interventions; and therefore, considered among the most lucrative opportunity areas for biopharmaceutical developers. Currently, there are over 20...

Cancer, one of the leading causes of death worldwide, claimed close to 10 million lives annually Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Presently, the success rate for CAR T-cell therapies is estimated to...

In 2020, close to 340 million tons of meat was estimated to be produced worldwide. Compared to the early 1960s (~70 million tons), this represents almost a 500% increase. As a result, raising animals for slaughter is estimated to be responsible for close to 15% of global greenhouse gas emissions. Animal farming also requires large areas of land, for grazing, which is often the cause of deforestation efforts. In this context, it is worth highlighting that raising cattle for beef and lamb meat pro...

The global aptamers market is estimated to grow from $0.92 billion in 2025 to reach $1.48 billion in 2026 and $12.78 billion by 2035, representing a higher CAGR of 27.0% during the forecast period. Over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity. Given the various advantages, aptamer-based therapeutics in th...

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of GvHD.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Dravet syndrome.

The “Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of soft tissue sarcoma.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cryptococcosis.

The “Pompe Disease: Pipeline Review, Developer Landscape and Competitive Insights, 2025-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Pompe Disease.

The “Amnesia: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Amnesia.

The non-crispr genome editing therapy market is estimated to be worth $451 million in 2022 and is expected to grow at CAGR of 18% during the forecast period. Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. In fact, there have been several advancements in the field of genome editing, which provide investigators the ability to introduce sequence-specific modifications into the genomes of a broad spectrum of c...

The myeloid cell targeting therapeutics market is estimated to be worth $652 million in 2022 and is expected to grow at CAGR of over 40% during the forecast period. With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches. Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune resp...

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig.

The metal and lipid nanoparticle manufacturing market (service) is estimated to be worth $2.1 billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 8.6% during the forecast period. A recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility...